MPS Pharmaa Ltd
Incorporated in 1997, MPS Pharmaa Ltd manufactures and sells pharmaceutical
products[1]
- Market Cap ₹ 3.46 Cr.
- Current Price ₹ 1.81
- High / Low ₹ 3.01 / 1.57
- Stock P/E
- Book Value ₹ 0.04
- Dividend Yield 0.00 %
- ROCE -13.1 %
- ROE -177 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 49.4 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 35.9%
- Company has a low return on equity of -61.4% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.24 | 1.35 | 2.84 | 4.09 | 0.83 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 11.43 | 1.84 | 9.72 | 4.62 | 1.56 | 0.67 | 4.14 | 0.71 | 0.95 | 0.80 | 0.77 | 0.95 | |
| Operating Profit | 0.81 | -0.49 | -6.88 | -0.53 | -0.73 | -0.67 | -4.14 | -0.68 | -0.95 | -0.80 | -0.77 | -0.95 |
| OPM % | 6.62% | -36.30% | -242.25% | -12.96% | -87.95% | -2,266.67% | ||||||
| 0.00 | 0.00 | 0.03 | 0.06 | 0.02 | 0.01 | 0.20 | 0.26 | 0.02 | 0.09 | 0.05 | 0.04 | |
| Interest | 1.08 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.65 | 0.62 | 0.59 | 0.59 | 0.59 | 0.57 | 0.56 | 0.51 | 0.15 | 0.15 | 0.15 | 0.15 |
| Profit before tax | -0.92 | -1.19 | -7.44 | -1.06 | -1.30 | -1.23 | -4.50 | -0.93 | -1.08 | -0.86 | -0.87 | -1.06 |
| Tax % | -26.09% | -0.84% | -0.81% | -17.92% | -3.85% | -5.69% | -1.78% | -84.95% | -1.85% | -2.33% | 3.45% | -3.77% |
| -0.68 | -1.19 | -7.39 | -0.87 | -1.25 | -1.17 | -4.42 | -0.14 | -1.05 | -0.83 | -0.90 | -1.02 | |
| EPS in Rs | -0.45 | -0.62 | -3.87 | -0.46 | -0.65 | -0.61 | -2.31 | -0.07 | -0.55 | -0.43 | -0.47 | -0.53 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 12% |
| 3 Years: | 1% |
| TTM: | -13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | 12% |
| 3 Years: | -8% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | -30% |
| 5 Years: | -34% |
| 3 Years: | -61% |
| Last Year: | -177% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.03 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 | 19.11 |
| Reserves | 4.17 | -0.13 | -7.50 | -8.35 | -9.58 | -10.75 | -15.16 | -15.29 | -16.32 | -17.14 | -18.03 | -19.04 |
| 7.78 | 6.65 | 2.90 | 2.90 | 2.51 | 2.53 | 5.68 | 5.81 | 6.77 | 7.27 | 7.46 | 7.52 | |
| 5.38 | 2.94 | 6.41 | 5.49 | 5.52 | 5.52 | 1.67 | 0.53 | 0.63 | 0.70 | 0.80 | 0.89 | |
| Total Liabilities | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.48 |
| 8.21 | 7.64 | 7.06 | 6.47 | 5.88 | 5.26 | 4.68 | 4.17 | 4.14 | 4.01 | 3.83 | 3.66 | |
| CWIP | 6.15 | 6.15 | 5.51 | 5.21 | 5.43 | 5.02 | 3.90 | 3.42 | 3.40 | 3.26 | 2.91 | 2.41 |
| Investments | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.92 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 | 0.54 |
| 17.08 | 13.86 | 7.43 | 6.55 | 5.33 | 5.21 | 2.18 | 2.03 | 2.11 | 2.13 | 2.06 | 1.87 | |
| Total Assets | 32.36 | 28.57 | 20.92 | 19.15 | 17.56 | 16.41 | 11.30 | 10.16 | 10.19 | 9.94 | 9.34 | 8.48 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.16 | 1.25 | 0.37 | -0.34 | 0.61 | -0.49 | -0.93 | -4.34 | -0.87 | -0.63 | -0.57 | -0.59 | |
| -0.44 | -0.05 | 0.63 | 0.30 | -0.22 | 0.46 | 1.54 | 0.46 | -0.10 | 0.12 | 0.38 | 0.52 | |
| -1.75 | -1.19 | -0.98 | 0.00 | -0.39 | 0.03 | -0.61 | 3.88 | 0.96 | 0.51 | 0.18 | 0.07 | |
| Net Cash Flow | -0.03 | 0.01 | 0.02 | -0.04 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 1.72 | 1.20 | 1.00 | -0.04 | 0.39 | -0.04 | 0.22 | -3.88 | -0.97 | -0.51 | -0.19 | -0.07 |
| CFO/OP | 267% | -292% | -5% | 64% | -84% | 73% | 22% | 638% | 92% | 79% | 74% | 62% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 229.02 | 1,154.48 | 532.08 | 344.47 | 1,147.77 | 365.00 | ||||||
| Inventory Days | 274.40 | 6,543.93 | 50.05 | 58.94 | 253.72 | 4,015.00 | 4,562.50 | |||||
| Days Payable | 123.03 | 556.19 | 15.95 | 14.48 | 71.22 | 876.00 | 1,825.00 | |||||
| Cash Conversion Cycle | 380.39 | 7,142.22 | 566.19 | 388.94 | 1,330.27 | 3,504.00 | ||||||
| Working Capital Days | 208.74 | 1,724.96 | -115.67 | -87.46 | -848.73 | -49,396.67 | ||||||
| ROCE % | 0.58% | -4.22% | -37.07% | -7.53% | -10.12% | -10.73% | -45.61% | -9.66% | -11.26% | -9.15% | -9.79% | -13.14% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Electricity Purchased for Plant Operations Units |
|
|||||
| Number of Employees Count |
||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Submitted Annual Secretarial Compliance Report for year ended 31 March 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 May - PFA Newspaper Publication w.r.t Audited Financial Results for the Quarter and Year ended 31st March, 2026
-
Announcement under Regulation 30 (LODR)-Change in Management
28 May - Board approved audited FY26 results, noted modified audit opinion, and reappointed internal auditor for FY27.
- SUBMISSION OF AUDITED FINANCIAL RESULTS FOR THE F.Y. ENDED 31.03.2026 28 May
-
Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2026 As Required U/R 33 Of The SEBI (LODR) Regulations, 2015
28 May - Board approved audited FY2026 results on 28 May 2026 and reappointed internal auditor Sanghi & Co.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
a) MPSPL (Formerly Advik Laboratories
Ltd) is in the business of manufacturing, marketing, trading, and export of Pharma Products.
b) The company has its manufacturing facility at Sohna.
c) It has various independent contract
/third-party manufacturers based across
the country